3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Genitourinary
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Neoplasms by Histologic Type
1
Neoplasms
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Bone Marrow Diseases
1
Interventions
Cyclophosphamide
9
ruxolitinib
7
Azacitidine
7
fludarabine phosphate
6
Whole-Body Irradiation
6
Peripheral Blood Stem Cell Transplantation
6
Mycophenolic Acid
6
navitoclax
5
fludarabine
5
Therapeutics
5
Busulfan
5
ponatinib
4
Melphalan
4
Tacrolimus
3
Stem Cell Transplantation
3
Patient Reported Outcome Measures
3
Mesna
3
Immunoenzyme Techniques
3
Flow Cytometry
3
Cyclosporine
3
Clofarabine
3
Antilymphocyte Serum
3
vosaroxin
2
trametinib
2
liposomal amphotericin B
2
dabrafenib
2
Watchful Waiting
2
Transplantation
2
Sirolimus
2
Psychiatric Rehabilitation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
BID protein, human
×
Myeloid
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts